Novel alpha radiopharmaceutical therapy shows promise in early-phase prostate cancer trial

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a trial published in The Journal of Nuclear Medicine's Late-Breaking Fast Track.

Read it at Medical Xpress ↗

← Front page